Detailed price information for Kalvista Pharmaceuticals Inc (KALV-Q) from The Globe and Mail including charting and trades.

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has today approved Ekterly (sebetralstat) 0for the ...

KalVista jumps 36% in a week after the FDA clears Ekterly, the first oral on-demand therapy for hereditary angioedema.

Received FDA approval of EKTERLY® (sebetralstat)-the first and only oral on-demand treatment for hereditary angioedema; U.S. launch underway - - Six additional global regulatory submissions under ...

FDA approval of EKTERLY makes KalVista Pharmaceuticals, Inc. the first to offer an oral on-demand HAE therapy. Click here to find out why KALV is a Strong Buy.

Detailed price information for Kalvista Pharmaceuticals Inc (KALV-Q) from The Globe and Mail including charting and trades.

Citizens JMP analyst Jonathan Wolleben raised the firm’s price target on KalVista (KALV) to $27 from $19 and keeps an Outperform rating on the ...

View the latest KalVista Pharmaceuticals Inc. (KALV) stock price, news, historical charts, analyst ratings and financial information from WSJ.

Trump announced a 25% tariff on goods from South Korea and Japan starting Aug. 1, citing the need to correct for long-standing U.S. trade deficits with the two countries. As of 2024, the goods deficit ...

President Donald Trump has signed House Resolution 1 (H.R. 1), the final version of which does not impose a moratorium on state legislation governing the use of AI. The bill does, however, restore the ...